2009
DOI: 10.1111/j.1445-5994.2009.01793.x
|View full text |Cite
|
Sign up to set email alerts
|

Baseline and salt‐stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: relation to disease severity

Abstract: Baseline and stimulated PON1 and ARE activities are reduced in patients with chronic liver disease. Serum ARE activity could be a suitable biomarker for the evaluation of the presence and severity of chronic liver damage.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
15
0

Year Published

2010
2010
2020
2020

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 25 publications
(16 citation statements)
references
References 19 publications
1
15
0
Order By: Relevance
“…To date, similar evaluation of POase and DZOase activities as diagnostic tests for sepsis was not performed. However, measurement of PON1 arylesterase activity was found to be an efficient test for identifying the presence and severity of chronic liver injury [6]. …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…To date, similar evaluation of POase and DZOase activities as diagnostic tests for sepsis was not performed. However, measurement of PON1 arylesterase activity was found to be an efficient test for identifying the presence and severity of chronic liver injury [6]. …”
Section: Discussionmentioning
confidence: 99%
“…Growing interest in the enzyme's importance is prompted by its role in lipid peroxidation and the development of atherosclerosis [5]. Decreased PON1 activity was also observed in liver disease [6, 7], acute pancreatitis [8], diabetes [9], chronic renal failure, and dialysis [10, 11]. So far, no data have been reported on the utility of serial PON1 measurement in surgical patients with sepsis.…”
Section: Introductionmentioning
confidence: 99%
“…PON1 enzyme levels can range widely even between individuals with the same PON1 phenotype [34] and PON1 phenotypes do not influence changes in PON1 associated with some clinical conditions such as hepatic disease [27,35]. However in substrates highly influenced by polymorphisms, such as paraoxon in humans, there is a potential for obtaining false high values of PON1 in populations with high frequency of PON1R when compared with populations with high frequency of PON1Q and vice versa [4].…”
Section: Characteristics Of the Substratesmentioning
confidence: 99%
“…However, use of paraoxon as substrate would not be optimal due to its toxicity (Camps et al, 2009) and the possibility of analyzer contamination (Mogarekar and Chawhan, 2013). Divergences in the diagnostic performance between different substrates have been described in certain diseases (Dantoine et al, 1998;Keskin et al, 2009). Therefore, comparative studies in which various substrates are used for PON1 measurements would be recommended when this enzyme is evaluated in a new disease.…”
Section: Introductionmentioning
confidence: 99%